-
CHMP highlights: May 2023MEDICINES |COMMITTEES
CHMP highlights: May 2023
-
CHMP highlights: May 2023MEDICINES |COMMITTEES
CHMP highlights: May 2023
EMA's human medicines committee (CHMP) recommended 2 new medicines for approval in the EU at its May 2023 meeting
-
Industry guidance to prevent medicine shortagesGuidance |Shortages
Industry guidance to prevent medicine shortages
-
Industry guidance to prevent medicine shortagesGuidance |Shortages
Industry guidance to prevent medicine shortages
EMA has published recommendations for marketing authorisation holders, wholesalers, distributors and manufacturers to prevent human medicine shortages and reduce their impact.
-
2022 annual report publishedEMA |About us
2022 annual report published
-
2022 annual report publishedEMA |About us
2022 annual report published
EMA has published its 2022 annual report that provides an overview of the Agency’s major achievements, key figures and contributions to public and animal health in Europe
-
End of COVID-19 public health emergencyCOVID-19 |Statement
End of COVID-19 public health emergency
-
End of COVID-19 public health emergencyCOVID-19 |Statement
End of COVID-19 public health emergency
EMA's Executive Director, Emer Cooke, issues a statement after the end of the Public Health Emergency of International Concern (PHEIC) for COVID-19 was declared by the WHO.
Latest news
-
List item26/05/2023
EMA business hours over Whit Monday, 29 May
The European Medicines Agency's (EMA) office is closed on Monday 29 May 2023. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number...
-
List item26/05/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023
Two new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended two medicines for approval at its May 2023 meeting. The committee recommended granting a marketing authorisation for Pylclari (piflufolastat (18F)),...
-
List item22/05/2023
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 May 2023
CVMP opinions on veterinary medicinal products Under Regulation (EU) 2019/6 The Committee adopted by consensus a positive opinion for a marketing authorisation application for Eluracat ( capromorelin tartrate ), from Elanco GmbH, a new product for...
-
List item17/05/2023
Guidance for industry to prevent and mitigate medicine shortages
EMA has published recommendations for industry on good practices to ensure continuity in the supply of human medicines, prevent shortages and reduce their impact . Medicine shortages are a global health problem and are increasingly affecting...
-
List item16/05/2023
EMA business hours over Ascension Day holidays, 18 and 19 May
The European Medicines Agency's (EMA) office is closed from 18:30 on Wednesday 17 May until 07:30 on Monday 22 May. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please...
-
List item15/05/2023
EMA annual report 2022 published
EMA published its annual report 2022 today. The report provides an overview of the Agency’s activities to protect and promote public and animal health in the European Union (EU). The digital report outlines the most important highlights regarding...
Information for you






Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal